0000950170-25-020484.txt : 20250214 0000950170-25-020484.hdr.sgml : 20250214 20250214090003 ACCESSION NUMBER: 0000950170-25-020484 CONFORMED SUBMISSION TYPE: SCHEDULE 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20250214 DATE AS OF CHANGE: 20250214 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Spyre Therapeutics, Inc. CENTRAL INDEX KEY: 0001636282 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464312787 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-89456 FILM NUMBER: 25623665 BUSINESS ADDRESS: STREET 1: 221 CRESCENT STREET STREET 2: BUILDING 23, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 6176515940 MAIL ADDRESS: STREET 1: 221 CRESCENT STREET STREET 2: BUILDING 23, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: Aeglea BioTherapeutics, Inc. DATE OF NAME CHANGE: 20150311 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: RTW INVESTMENTS, LP CENTRAL INDEX KEY: 0001493215 ORGANIZATION NAME: IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G/A BUSINESS ADDRESS: STREET 1: 40 10TH AVENUE STREET 2: 7TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 BUSINESS PHONE: 646-597-6980 MAIL ADDRESS: STREET 1: 40 10TH AVENUE STREET 2: 7TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 FORMER COMPANY: FORMER CONFORMED NAME: RTW INVESTMENTS, LLC DATE OF NAME CHANGE: 20100602 SCHEDULE 13G/A 1 primary_doc.xml SCHEDULE 13G/A 0000902664-24-001536 0001493215 XXXXXXXX LIVE 1 Common Stock, par value $0.0001 per share 12/31/2024 0001636282 Spyre Therapeutics, Inc. 00773J202 221 Crescent Street, Building 23 Suite 105 Waltham MA 02453 Rule 13d-1(b) RTW Investments, LP DE 0 3621996 0 3621996 3621996 N 6.2 PN IA Roderick Wong, M.D. X1 0 3621996 0 3621996 3621996 N 6.2 IN HC Spyre Therapeutics, Inc. 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453 This statement is filed by: (i) RTW Investments, LP ("RTW Investments"), a Delaware limited partnership and the investment adviser to certain funds (the "RTW Funds"), with respect to shares of Common Stock, par value $0.0001 per share (the "Shares") of Spyre Therapeutics, Inc. (the "Company") directly held by the RTW Funds; and (ii) Roderick Wong, M.D. ("Dr. Wong"), the Managing Partner and Chief Investment Officer of RTW Investments, with respect to the Shares directly held by the RTW Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, as amended, the beneficial owner of the Shares reported herein. The address of the business office of each of the Reporting Persons is 40 10th Avenue, Floor 7, New York, New York 10014. RTW Investments is a Delaware limited partnership. Dr. Wong is a citizen of the United States. N IA HC The information required by Item 4(a) is set forth in Rows 5 - 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentages set forth in Row 11 of the cover pages are calculated based upon 58,670,608 Shares outstanding as of November 18, 2024 as reported in the Company's prospectus filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on November 19, 2024. RTW Investments: 6.2% Dr. Wong: 6.2 RTW Investments: 0 Dr. Wong: 0 RTW Investments: 3,621,996 Shares Dr. Wong: 3,621,996 Shares RTW Investments: 0 Dr. Wong: 0 RTW Investments: 3,621,996 Shares Dr. Wong: 3,621,996 Shares Y N See Item 2. The RTW Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. RTW Investments, LP /s/ Roderick Wong, M.D. 02/14/2025 Roderick Wong, M.D. /s/ Roderick Wong, M.D. 02/14/2025